Stroke: Expanded indications for stroke thrombolysis—what next?

Restrictions to thrombolytic therapy for stroke—recommended only up to 4.5 h after onset and in those under 80 years of age—limit its use. Results from a recent trial support expansion of both the inclusion criteria and the time window for thrombolytic therapy, but further research is needed.

[1]  C. Ikonomidou,et al.  Antiepileptic Drugs and Apoptosis in the Developing Brain , 2003, Annals of the New York Academy of Sciences.

[2]  P. Sandercock,et al.  Third International Stroke Trial , 2006, International journal of stroke : official journal of the International Stroke Society.

[3]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[4]  Geoffrey A. Donnan,et al.  A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND) , 2012, International journal of stroke : official journal of the International Stroke Society.

[5]  S. Warach,et al.  Vascular Occlusion Enables Selecting Acute Ischemic Stroke Patients for Treatment With Desmoteplase , 2012, Stroke.

[6]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[7]  P. Sandercock,et al.  Statistical Analysis Plan for the Third International Stroke Trial (IST-3); Part of a ‘Thread’ of Reports of the Trial , 2012, International journal of stroke : official journal of the International Stroke Society.

[8]  G. Donnan,et al.  Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. , 2012, The New England journal of medicine.

[9]  S. Davis,et al.  Plasminogen Activation and Thrombolysis for Ischemic Stroke , 2012, International journal of stroke : official journal of the International Stroke Society.

[10]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[11]  G. Donnan,et al.  A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.

[12]  Mairead Kiely,et al.  An updated systematic review and meta-analysis of the efficacy of vitamin D food fortification. , 2012, The Journal of nutrition.